United States Oncology Diagnostics Market 2016-2017 - Forecast to 2021

News provided by

Aug 11, 2017, 10:15 ET

DUBLIN, August 11, 2017 /PRNewswire/ --

The "US Oncology Diagnostics Market - Forecast to 2021" report has been added to Research and Markets' offering.

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual's cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories.

Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes.

Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States.

The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.

Highlights of the report include:

Annual biopsies and projection estimates for all the cancer types (2016-2021)
Revenue forecast by technology type (molecular vs non-molecular) and by intended use (screening, prognosis, diagnosis, therapy selection, and therapy monitoring/management)
Key trends and growth opportunities
Game-changing companies
Disruptive technologies and business models
Emerging biomarkers and companion diagnostic development landscape
Pricing analysis
Epidemiology studies for all cancer types (2016-2021)
Strategic recommendations and future outlook of cancer market

Key questions this study will answer include:

Which are the cancer types that hold the highest potential in terms of revenue and growth?
What are the tests and technologies used to screen, diagnose, and predict therapy in each of the cancers? Where are the new developments taking place?
What does the current and prospective competitive landscape look like? What are the approaches being taken by participants to counter competitive threats?
How is the landscape for mergers, acquisitions, and collaborations?
What are the emerging biomarker opportunities for breast, prostate, cervical, ovarian, lung, and colorectal cancer for developing new tests?
Which are the companies that are driving innovation within each cancer type?

Key Topics Covered:

1. Executive Summary

Market Highlights
Scope and Segmentation
Top Economic Motivators for Cancer Testing
Trends Driving Cancer Testing
Examples of Competitive Developments
Future Trends - 3 Big Predictions
Key Questions this Study will Answer

2. US Oncology Diagnostics Market Overview

Trends/Factors Impacting the Cancer Diagnostics Market
Cancer Market Trends
Market Drivers
Market Restraints
Notable Activities
Top Predictions for the Cancer Diagnostics Market
Objectives - Cancer Moonshot Program
Opportunities - Cancer Moonshot Program
Liquid Biopsy Technology - Investments

3. Overview of Competitors

Competitor Matrix
Competitor Matrix - Technology Used

4. Total Cancer Diagnostics Market

Forecast Assumptions
Revenue Forecast
Percent Revenue Forecast by Cancer Segment
Revenue Forecast by Cancer Segment
Total Biopsy Volume Snap Shot

5. Breast Cancer

Breast Cancer - Segmentation
Breast Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Companion Diagnostics - Strategy and Partnerships
Emerging Biomarkers

6. Ovarian Cancer

Ovarian Cancer - Segmentation
Ovarian Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Companion Diagnostics - Strategy and Partnerships

7. Cervical Cancer

Cervical Cancer - Segmentation
Cervical Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch

8. Colorectal Cancer

Colorectal Cancer - Segmentation
Colorectal Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Companion Diagnostics - Strategy and Partnerships

9. Prostate Cancer

Prostate Cancer - Segmentation
Prostate Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Future Trends

10. Lung Cancer

Lung Cancer - Segmentation
Lung Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Companion Diagnostics - Strategy and Partnerships

11. Companion Biomarker Opportunities in Drug Development

Summary of Therapeutic Pipeline with Companion Biomarker by Cancer Type
Summary of Therapeutic Pipeline by Phase
Summary of Therapeutic Targets
Summary of Therapeutic Pipeline with Companion Biomarker by Tumor Type
Summary of Tumor Types with Targeted Therapeutics
Companion Diagnostic Targets by Company
Companion Diagnostic Partnerships
Approved Companion Diagnostic Tests - United States

12. Future Outlook and Emerging Opportunities

Keys Factors for Success in Cancer Diagnostic Space
Future Outlook and Emerging Opportunities

13. Appendix

List of Abbreviations
Breast Cancer Epidemiology
Breast Cancer - US Incidence and Forecast, 2016-2021
Breast Cancer - Biomarkers and Assays
Ovarian Cancer Epidemiology
Ovarian Cancer - US Incidence and Forecast, 2016-2021
Ovarian Cancer - Biomarkers and Assays
Cervical Cancer Epidemiology
Cervical Cancer - US Incidence and Forecast, 2016-2021
Cervical Cancer - Biomarkers and Assays
Colorectal Cancer Epidemiology
Colorectal Cancer - US Incidence and Forecast, 2016-2021
Colorectal Cancer - Biomarkers and Assays
Prostate Cancer Epidemiology
Prostate Cancer - US Incidence and Forecast, 2016-2021
Prostate Cancer - Biomarkers and Assays
Lung Cancer Epidemiology
Lung Cancer - US Incidence and Forecast, 2016-2021
Lung Cancer - Biomarkers and Assays
Companies Represented in the Samples Studies

Companies Mentioned

Agendia
Becton Dickinson
Biodesix
Cancer Genetics
Epigenomics
Exact Science
Foundation Medicine
Genomic Health
MDxHealth
Metamark Genetics
Myriad Genetics
nanoString Technologies
Provista Diagnostics
Rosetta Genomics

For more information about this report visit: https://www.researchandmarkets.com/research/trsr3d/us_oncology

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets